The Skinny on Mouse Collaborations

Courtesy of Moffa Photography Researchers have until August 1st to make their views known on a proposed policy for sharing genetically modified mice and mutant strains bred for research. The policy applies to both knockout and transgenic mice, inbred and mutant strains, as well as associated data and tools, such as DNA vectors and embryonic stem cells. Early reviews of the National Institutes of Health's draft statement from professional organizations were positive, perhaps because the agency

Written byPeg Brickley
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Researchers have until August 1st to make their views known on a proposed policy for sharing genetically modified mice and mutant strains bred for research. The policy applies to both knockout and transgenic mice, inbred and mutant strains, as well as associated data and tools, such as DNA vectors and embryonic stem cells.

Early reviews of the National Institutes of Health's draft statement from professional organizations were positive, perhaps because the agency couched the statement as a strong suggestion to researchers, rather than as a rule for NIH grant applicants. "Unnecessary delay of publication and prolonged exclusive use of the mice are not in the best interests of the research community or the public health," says the NIH on its extensive Web site explaining the intricacies of the policy (www.nih.gov/science/models/mouse/sharing/index.html).

The mouse-sharing policy clarifies NIH's position on one of the most important research tools in the lab. Mice data are ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies